Abstract Details
|
Michelle Blumenschine
(Columbia University)
PRESENTER |
No disclosure on file |
| Walter R. Royal III, MD | No disclosure on file |
| Jacqueline Montes, PT, EdD, NCS (Columbia University Medical Center) | Ms. Montes has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Ms. Montes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for F. Hoffman LaRoche. Ms. Montes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Scholar Rock. Ms. Montes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. The institution of Ms. Montes has received research support from NIH/NICHD. The institution of Ms. Montes has received research support from Muscular Dystrophy Association. The institution of Ms. Montes has received research support from Cure SMA. |
| Ashwini K. Rao (Rehabilitation Medicine) | No disclosure on file |
| Elizabeth Harrison, MD (UPMC Children's Hospital of Pittsburgh) | Dr. Harrison has nothing to disclose. |
| Kristin Engelstad | No disclosure on file |
| Darryl C. De Vivo, MD, FAAN (Columbia University) | Dr. De Vivo has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen and Novartis. Dr. De Vivo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Aspa Therapeutics. |